Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions Meeting Abstract
| Authors: | Javle, M.; Kelley, R. K.; Roychowdhury, S.; Weiss, K. H.; Abou-Alfa, G. K.; Macarulla, T.; Sadeghi, S.; Waldschmidt, D.; Zhu, A. X.; Goyal, L.; Borad, M.; Yong, W. P.; Borbath, I.; El-Khoueiry, A.; Philip, P.; Moran, S.; Ye, Y.; Ising, M.; Lewis, N.; Bekaii-Saab, T. |
| Abstract Title: | Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy424.030 |
| Language: | English |
| ACCESSION: | WOS:000459277304386 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy424.030 |
| Notes: | Meeting Abstract: LBA28 -- Appears on page viii720 of the abstract book -- Source: Wos |
